Mark A. Goldsmith, President and Chief Executive Officer of Revolution Medicines, Inc. (NASDAQ:RVMD), executed a sale of 120,000 shares of the company's common stock on April 15, 2026, generating proceeds of $18,010,488 at a sale price of $150.0874 per share.
On that same date, Goldsmith also exercised stock options to acquire an additional 120,000 shares of Revolution Medicines common stock. The option exercises consisted of 23,244 shares at an exercise price of $4.09 per share and 96,756 shares at an exercise price of $4.73 per share, with the aggregate cost for these exercises totaling $552,723.
Following the combination of the sale and the option exercises reported for April 15, 2026, Goldsmith's reported ownership stands at 276,698 shares held directly and 722,908 shares held indirectly through various trusts.
Separately from these insider transactions, Revolution Medicines has completed significant capital markets activity. The company raised approximately $2.1 billion through concurrent public offerings of common stock and the issuance of convertible senior notes. The equity component involved the sale of slightly more than 12 million shares of common stock at $142 per share, producing roughly $1.7 billion in gross proceeds. In addition, Revolution Medicines issued $500 million in convertible senior notes due 2033.
The company had previously announced that these offerings were priced to bring in about $2 billion in gross proceeds; the final reported aggregate was described as approximately $2.1 billion.
In clinical developments reported alongside the financing activity, Revolution Medicines disclosed positive Phase III trial results for daraxonrasib in pancreatic cancer, with the trial meeting key survival endpoints for patients in the study.
Following the Phase III announcement, several equity research firms updated their views. Mizuho reiterated an Outperform rating with a $140 price target. H.C. Wainwright raised its price target to $169 while maintaining a Buy rating. RBC Capital increased its price target to $162. These analyst actions were cited in relation to the company's strengthened position in the RAS inhibitor area.
Taken together, the insider transactions, the sizeable capital raise, and the positive Phase III data mark a period of active corporate and investor focus on Revolution Medicines.